Bruker Corp Unveils MyGenius PRO®: A Leap in Molecular Diagnostics
1. Introduction
In a significant advancement for the field of molecular diagnostics, Bruker Corporation (Nasdaq: BRKR) announced the European launch of its MyGenius PRO® system at the ESCMID Global 2026 conference. This new high-throughput, fully automated sample-to-answer (S2A) molecular diagnostics system is poised to transform infectious disease testing by enhancing laboratory efficiency and supporting increased testing volumes.
2. MyGenius PRO®: Features and Capabilities
The MyGenius PRO® system is built on the foundation of PCR (Polymerase Chain Reaction) technology, which is integral to the rapid diagnosis of infectious diseases. Key features of the system include:
- Higher Throughput: The MyGenius PRO® enables continuous loading of samples, consumables, and reagents, allowing laboratories to handle a larger volume of tests without interruption.
- Random-Access Operation: Laboratories can process samples as they come in, enhancing flexibility and efficiency.
- Comprehensive Medical Menu: At launch, the system will offer assays for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) from whole blood, as well as BK virus (BKV) from urine, specifically targeting diagnostic testing in immunocompromised patients.
Bruker has ambitious plans for rapid menu expansion throughout 2026, with the addition of assays for Human Immunodeficiency Virus type 1 (HIV-1), Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human Herpesvirus 6 (HHV-6), among others.
3. Collaborative Development
The MyGenius PRO® platform is a result of collaborative efforts between Bruker and Hitachi High-Tech Corporation. This partnership merges Bruker's expertise in molecular assays and diagnostics with Hitachi's strengths in automation and engineering. In Japan, Hitachi High-Tech plans to introduce the platform under the brand LABOSPECT GA-5, further extending the reach of Bruker's molecular diagnostic solutions in compliance with local regulations.
4. Industry Insights
Dr. Pierangelo Clerici, President of the Italian Association of Clinical Microbiologists (AMCLI), highlighted the critical role of high-throughput systems in microbiology laboratories. He stated, “Timely diagnosis is critical in microbiology and virology. Fully automated sample-to-result solutions improve turnaround time and support faster clinical response and effective infection monitoring, while enabling laboratories to streamline workflows and ensure compliance with IVDR regulations.”
5. Broader Impact on Bruker’s Strategy
The launch of MyGenius PRO® represents a pivotal moment in Bruker’s Microbiology & Infection Diagnostics strategy. This new system complements Bruker’s existing portfolio, which includes the InGenius® and BeGenius® systems, as well as a rapidly growing CE-IVD assay menu and innovative LiquidArray® assays for advanced multiplexing. Together, these offerings position Bruker as a leader in the molecular diagnostics space, addressing the needs of healthcare providers for efficient and reliable testing solutions.
6. Conclusion
With the introduction of MyGenius PRO®, Bruker Corporation is set to enhance its role in the diagnostics landscape, providing laboratories with cutting-edge technology to meet the challenges of infectious disease testing. As the company continues to innovate, the MyGenius PRO® system is expected to play a crucial role in improving patient outcomes through timely and accurate diagnostics.
For more information about Bruker’s groundbreaking solutions and initiatives in the molecular diagnostics sector, visit Bruker’s website.
